Home » EUFLEXXA STUDY RESULTS REPORTED
EUFLEXXA STUDY RESULTS REPORTED
A head-to-head study has demonstrated the efficacy and greater tolerability of Euflexxa (highly purified hyaluronan) compared to Synvisc, an avian-derived hyaluronan and the leading hyaluronic acid (HA) product in its class for the treatment of osteoarthritis (OA) knee pain.
In the 12-week trial of 321 patients, Euflexxa showed statistically significant advantages over Synvisc. More patients treated with Euflexxa were symptom-free, there was a lower incidence of joint effusion, fewer patients required supplemental simple analgesics, and more patients reported being "very satisfied." The study was published in the journal Osteoarthritis and Cartilage.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May